Progress on pursuit of human cytomegalovirus vaccines for prevention of congenital infection and disease

Vaccine

Volumn 32, Issue 22, 2014, Pages 2525-2533

  Fu, Tong Ming ^a   An, Zhiqiang ^b   Wang, Dai ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

^b UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

Congenital infection and disease; Human cytomegalovirus; Neutralizing antibodies; T cells; Vaccine

Indexed keywords

CYTOMEGALOVIRUS VACCINE; DNA VACCINE; ENDOTHELIAL CELL ANTIBODY; GB VACCINE; MF59 VACCINE; RECOMBINANT VACCINE; SUBUNIT VACCINE; TOWNE VACCINE; UNCLASSIFIED DRUG; VIRUS VACCINE;

CONGENITAL INFECTION; CYTOMEGALOVIRUS INFECTION; DRUG DESIGN; DRUG EFFICACY; ENDOTHELIUM CELL; EPITHELIUM CELL; HUMAN; HUMAN CYTOMEGALOVIRUS; IMMUNE RESPONSE; INFECTION PREVENTION; INNATE IMMUNITY; MATERNAL DISEASE; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REVIEW; VACCINATION; VERTICAL TRANSMISSION; VIRUS TRANSMISSION;

CONGENITAL INFECTION AND DISEASE; HUMAN CYTOMEGALOVIRUS; NEUTRALIZING ANTIBODIES; T-CELLS; VACCINE;

ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; CYTOMEGALOVIRUS INFECTIONS; CYTOMEGALOVIRUS VACCINES; DISEASE TRANSMISSION, INFECTIOUS; FEMALE; HUMANS; IMMUNITY, INNATE; INFECTIOUS DISEASE TRANSMISSION, VERTICAL; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; VACCINES, ATTENUATED; VACCINES, SYNTHETIC;

EID: 84898545160     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2014.03.057     Document Type: Review

References (125)

1. Kenneson A., Cannon M.J. Review and meta-analysis of the epidemiology of congenital cytomegalovirus (CMV) infection. Rev Med Virol 2007, 17:253-276.
2. Institute of Medicine CtSPfV Vaccines for the 21st century: a tool for decisionmaking 2001, National Academies Press, Washington DC.
3. Arvin A.M., Fast P., Myers M., Plotkin S., Rabinovich R. Vaccine development to prevent cytomegalovirus disease: report from the National Vaccine Advisory Committee. Clin Infect Dis 2004, 39:233-239.
4. Kotton C.N. Management of cytomegalovirus infection in solid organ transplantation. Nat Rev Nephrol 2010, 6:711-721.
5. Beam E., Razonable R.R. Cytomegalovirus in solid organ transplantation: epidemiology, prevention, and treatment. Curr Infect Dis Rep 2012, 14:633-641.
6. Ariza-Heredia E.J., Nesher L., Chemaly R.F. Cytomegalovirus diseases after hematopoietic stem cell transplantation: a mini-review. Cancer Lett 2014, 342:1-8.
7. Opelz G., Dohler B., Ruhenstroth A. Cytomegalovirus prophylaxis and graft outcome in solid organ transplantation: a collaborative transplant study report. Am J Transpl: Off J Am Soc Transpl Am Soc Transpl Surg 2004, 4:928-936.
8. Krause P.R., Bialek S.R., Boppana S.B., Griffiths P.D., Laughlin C.A., Ljungman P., et al. Priorities for CMV vaccine development. Vaccine 2013, 32:4-10.
9. Cha T.A., Tom E., Kemble G.W., Duke G.M., Mocarski E.S., Spaete R.R. Human cytomegalovirus clinical isolates carry at least 19 genes not found in laboratory strains. J Virol 1996, 70:78-83.
10. Chee M.S., Bankier A.T., Beck S., Bohni R., Brown C.M., Cerny R., et al. Analysis of the protein-coding content of the sequence of human cytomegalovirus strain AD169. Curr Top Microbiol Immunol 1990, 154:125-169.
11. Dolan A., Cunningham C., Hector R.D., Hassan-Walker A.F., Lee L., Addison C., et al. Genetic content of wild-type human cytomegalovirus. J Gen Virol 2004, 85:1301-1312.
12. Gatherer D., Seirafian S., Cunningham C., Holton M., Dargan D.J., Baluchova K., et al. High-resolution human cytomegalovirus transcriptome. Proc Natl Acad Sci U S A 2011, 108:19755-19760.
13. Murphy E., Yu D., Grimwood J., Schmutz J., Dickson M., Jarvis M.A., et al. Coding potential of laboratory and clinical strains of human cytomegalovirus. Proc Natl Acad Sci U S A 2003, 100:14976-14981.
14. Stern-Ginossar N., Weisburd B., Michalski A., Le V.T., Hein M.Y., Huang S.X., et al. Decoding human cytomegalovirus. Science 2012, 338:1088-1093.
15. Varnum S.M., Streblow D.N., Monroe M.E., Smith P., Auberry K.J., Pasa-Tolic L., et al. Identification of proteins in human cytomegalovirus (HCMV) particles: the HCMV proteome. J Virol 2004, 78:10960-10966.
16. Sylwester A.W., Mitchell B.L., Edgar J.B., Taormina C., Pelte C., Ruchti F., et al. Broadly targeted human cytomegalovirus-specific CD4+ and CD8+ T cells dominate the memory compartments of exposed subjects. J Exp Med 2005, 202:673-685.
17. Gretch D.R., Kari B., Gehrz R.C., Stinski M.F. A multigene family encodes the human cytomegalovirus glycoprotein complex gcII (gp 47-52 complex). J Virol 1988, 62:1956-1962.
18. Huber M.T., Compton T. Characterization of a novel third member of the human cytomegalovirus glycoprotein H-glycoprotein L complex. J Virol 1997, 71:5391-5398.
19. Huber M.T., Compton T. The human cytomegalovirus UL74 gene encodes the third component of the glycoprotein H-glycoprotein L-containing envelope complex. J Virol 1998, 72:8191-8197.
20. Li L., Nelson J.A., Britt W.J. Glycoprotein H-related complexes of human cytomegalovirus: identification of a third protein in the gCIII complex. J Virol 1997, 71:3090-3097.
21. Hahn G., Revello M.G., Patrone M., Percivalle E., Campanini G., Sarasini A., et al. Human cytomegalovirus UL131-128 genes are indispensable for virus growth in endothelial cells and virus transfer to leukocytes. J Virol 2004, 78:10023-10033.
22. Wang D., Shenk T. Human cytomegalovirus virion protein complex required for epithelial and endothelial cell tropism. Proc Natl Acad Sci U S A 2005, 102:18153-18158.
23. Fouts A.E., Chan P., Stephan J.P., Vandlen R., Feierbach B. Antibodies against the gH/gL/UL128/UL130/UL131 Complex Comprise the Majority of the Anti-Cytomegalovirus (Anti-CMV) Neutralizing Antibody Response in CMV Hyperimmune Globulin. J Virol 2012, 86:7444-7447.
24. Revello M.G., Gerna G. Diagnosis and management of human cytomegalovirus infection in the mother, fetus, and newborn infant. Clin Microbiol Rev 2002, 15:680-715.
25. Ross S.A., Arora N., Novak Z., Fowler K.B., Britt W.J., Boppana S.B. Cytomegalovirus reinfections in healthy seroimmune women. J Infect Dis 2010, 201:386-389.
26. Mussi-Pinhata M.M., Yamamoto A.Y., Moura Brito R.M., de Lima Isaac M., de Carvalho e Oliveira P.F., Boppana S., et al. Birth prevalence and natural history of congenital cytomegalovirus infection in a highly seroimmune population. Clin Infect Dis 2009, 49:522-528.
27. Boppana S.B., Rivera L.B., Fowler K.B., Mach M., Britt W.J. Intrauterine transmission of cytomegalovirus to infants of women with preconceptional immunity. N Engl J Med 2001, 344:1366-1371.
28. Ross S.A., Fowler K.B., Ashrith G., Stagno S., Britt W.J., Pass R.F., et al. Hearing loss in children with congenital cytomegalovirus infection born to mothers with preexisting immunity. J Pediatr 2006, 148:332-336.
29. Yamamoto A.Y., Mussi-Pinhata M.M., Boppana S.B., Novak Z., Wagatsuma V.M., de Frizzo Oliveira P., et al. Human cytomegalovirus reinfection is associated with intrauterine transmission in a highly cytomegalovirus-immune maternal population. Am J Obstet Gynecol 2010, 202. 297 e1-8.
30. Yamamoto A.Y., Mussi-Pinhata M.M., de Lima Isaac M., Amaral F.R., Carvalheiro C.G., Aragon D.C., et al. Congenital cytomegalovirus infection as a cause of sensorineural hearing loss in a highly immune population. Pediatr Infect Dis J 2011, 30:1043-1046.
31. Mocarski E.S., Shenk T., Pass R.F. Cytomegaloviruses. Fields virology 2007, 2701-2772. Lippincott Williams & Wilkins, Philadelphia. D.M. Knipes, P.M. Howley (Eds.).
32. Griffiths P., Plotkin S., Mocarski E., Pass R., Schleiss M., Krause P., et al. Desirability and feasibility of a vaccine against cytomegalovirus. Vaccine 2013, 31(Suppl. 2):B197-B203.
33. Adler S.P., Starr S.E., Plotkin S.A., Hempfling S.H., Buis J., Manning M.L., et al. Immunity induced by primary human cytomegalovirus infection protects against secondary infection among women of childbearing age. J Infect Dis 1995, 171:26-32.
34. Fowler K.B., Stagno S., Pass R.F. Maternal immunity and prevention of congenital cytomegalovirus infection. J Am Med Assoc 2003, 289:1008-1011.
35. Fowler K.B., Stagno S., Pass R.F., Britt W.J., Boll T.J., Alford C.A. The outcome of congenital cytomegalovirus infection in relation to maternal antibody status. N Engl J Med 1992, 326:663-667.
36. Plotkin S.A., Starr S.E., Friedman H.M., Gonczol E., Weibel R.E. Protective effects of Towne cytomegalovirus vaccine against low-passage cytomegalovirus administered as a challenge. J Infect Dis 1989, 159:860-865.
37. Tang A., Li F., Freed D.C., Finnefrock A.C., Casimiro D.R., Wang D., et al. A novel high-throughput neutralization assay for supporting clinical evaluations of human cytomegalovirus vaccines. Vaccine 2011, 29:8350-8356.
38. Plotkin S.A. Correlates of protection induced by vaccination. Clin Vaccine Immunol 2010, 17:1055-1065.
39. Schleiss M.R., Heineman T.C. Progress toward an elusive goal: current status of cytomegalovirus vaccines. Expert Rev Vaccines 2005, 4:381-406.
40. Elek S.D., Stern H. Development of a vaccine against mental retardation caused by cytomegalovirus infection in utero. Lancet 1974, 1:1-5.
41. Neff B.J., Weibel R.E., Buynak E.B., McLean A.A., Hilleman M.R. Clinical and laboratory studies of live cytomegalovirus vaccine Ad-169. Proc Soc Exp Biol Med 1979, 160:32-37.
42. Plotkin S.A., Farquhar J., Horberger E. Clinical trials of immunization with the Towne 125 strain of human cytomegalovirus. J Infect Dis 1976, 134:470-475.
43. Gerna G., Percivalle E., Sarasini A., Baldanti F., Campanini G., Revello M.G. Rescue of human cytomegalovirus strain AD169 tropism for both leukocytes and human endothelial cells. J Gen Virol 2003, 84:1431-1436.
44. Gerna G., Percivalle E., Sarasini A., Baldanti F., Revello M.G. The attenuated Towne strain of human cytomegalovirus may revert to both endothelial cell tropism and leuko- (neutrophil- and monocyte-) tropism in vitro. J Gen Virol 2002, 83:1993-2000.
45. Wang D., Shenk T. Human cytomegalovirus UL131 open reading frame is required for epithelial cell tropism. J Virol 2005, 79:10330-10338.
46. Plotkin S.A., Huang E.S. Cytomegalovirus vaccine virus (Towne strain) does not induce latency. J Infect Dis 1985, 152:395-397.
47. Goodrum F., Reeves M., Sinclair J., High K., Shenk T. Human cytomegalovirus sequences expressed in latently infected individuals promote a latent infection in vitro. Blood 2007, 110:937-945.
48. Gonczol E., Ianacone J., Furlini G., Ho W., Plotkin S.A. Humoral immune response to cytomegalovirus Towne vaccine strain and to Toledo low-passage strain. J Infect Dis 1989, 159:851-859.
49. Cui X., Meza B.P., Adler S.P., McVoy M.A. Cytomegalovirus vaccines fail to induce epithelial entry neutralizing antibodies comparable to natural infection. Vaccine 2008, 26:5760-5766.
50. Jacobson M.A., Sinclair E., Bredt B., Agrillo L., Black D., Epling C.L., et al. Antigen-specific T cell responses induced by Towne cytomegalovirus (CMV) vaccine in CMV-seronegative vaccine recipients. J Clin Virol 2006, 35:332-337.
51. Quinnan G.V., Delery M., Rook A.H., Frederick W.R., Epstein J.S., Manischewitz J.F., et al. Comparative virulence and immunogenicity of the Towne strain and a nonattenuated strain of cytomegalovirus. Ann Internal Med 1984, 101:478-483.
52. Plotkin S.A., Higgins R., Kurtz J.B., Morris P.J., Campbell D.A., Shope T.C., et al. Multicenter trial of Towne strain attenuated virus vaccine in seronegative renal transplant recipients. Transplantation 1994, 58:1176-1178.
53. Cui X., Adler S.P., Davison A.J., Smith L., Habib el S.E., McVoy M.A. Bacterial artificial chromosome clones of viruses comprising the Towne cytomegalovirus vaccine. J Biomed Biotechnol 2012, 2012:428498.
54. Kemble G., Duke G., Winter R., Spaete R. Defined large-scale alterations of the human cytomegalovirus genome constructed by cotransfection of overlapping cosmids. J Virol 1996, 70:2044-2048.
55. Heineman T.C., Schleiss M., Bernstein D.I., Spaete R.R., Yan L., Duke G., et al. A phase 1 study of 4 live, recombinant human cytomegalovirus Towne/Toledo chimeric vaccines. J Infect Dis 2006, 193:1350-1360.
56. Gerna G., Lilleri D., Fornara C., Comolli G., Lozza L., Campana C., et al. Monitoring of human cytomegalovirus-specific CD4 and CD8 T-cell immunity in patients receiving solid organ transplantation. Am J Transpl: Off J Am Soc Transpl Am Soc Transpl Surg 2006, 6:2356-2364.
57. Gerna G., Percivalle E., Lilleri D., Lozza L., Fornara C., Hahn G., et al. Dendritic-cell infection by human cytomegalovirus is restricted to strains carrying functional UL131-128 genes and mediates efficient viral antigen presentation to CD8+ T cells. J Gen Virol 2005, 86:275-284.
58. Spaete R.R., Saxena A., Scott P.I., Song G.J., Probert W.S., Britt W.J., et al. Sequence requirements for proteolytic processing of glycoprotein B of human cytomegalovirus strain Towne. J Virol 1990, 64:2922-2931.
59. Spaete R.R., Thayer R.M., Probert W.S., Masiarz F.R., Chamberlain S.H., Rasmussen L., et al. Human cytomegalovirus strain Towne glycoprotein B is processed by proteolytic cleavage. Virology 1988, 167:207-225.
60. Frey S.E., Harrison C., Pass R.F., Yang E., Boken D., Sekulovich R.E., et al. Effects of antigen dose and immunization regimens on antibody responses to a cytomegalovirus glycoprotein B subunit vaccine. J Infect Dis 1999, 180:1700-1703.
61. Pass R.F., Duliege A.M., Boppana S., Sekulovich R., Percell S., Britt W., et al. A subunit cytomegalovirus vaccine based on recombinant envelope glycoprotein B and a new adjuvant. J Infect Dis 1999, 180:970-975.
62. Sabbaj S., Pass R.F., Goepfert P.A., Pichon S. Glycoprotein B vaccine is capable of boosting both antibody and CD4 T-cell responses to cytomegalovirus in chronically infected women. J Infect Dis 2011, 203:1534-1541.
63. Pass R.F., Zhang C., Evans A., Simpson T., Andrews W., Huang M.L., et al. Vaccine prevention of maternal cytomegalovirus infection. N Engl J Med 2009, 360:1191-1199.
64. Griffiths P.D., Stanton A., McCarrell E., Smith C., Osman M., Harber M., et al. Cytomegalovirus glycoprotein-B vaccine with MF59 adjuvant in transplant recipients: a phase 2 randomised placebo-controlled trial. Lancet 2011, 377:1256-1263.
65. Heldwein E.E., Lou H., Bender F.C., Cohen G.H., Eisenberg R.J., Harrison S.C. Crystal structure of glycoprotein B from herpes simplex virus 1. Science 2006, 313:217-220.
66. Potzsch S., Spindler N., Wiegers A.K., Fisch T., Rucker P., Sticht H., et al. B cell repertoire analysis identifies new antigenic domains on glycoprotein B of human cytomegalovirus which are target of neutralizing antibodies. PLoS Pathog 2011, 7:e1002172.
67. Furebring C., Speckner A., Mach M., Sandlie I., Norderhaug L., Borrebaeck C.A., et al. Antibody-mediated neutralization of cytomegalovirus: modulation of efficacy induced through the IgG constant region. Mol Immunol 2002, 38:833-840.
68. Axelsson F., Adler S.P., Lamarre A., Ohlin M. Humoral immunity targeting site I of antigenic domain 2 of glycoprotein B upon immunization with different cytomegalovirus candidate vaccines. Vaccine 2007, 26:41-46.
69. Ryckman B.J., Rainish B.L., Chase M.C., Borton J.A., Nelson J.A., Jarvis M.A., et al. Characterization of the human cytomegalovirus gH/gL/UL128-131 complex that mediates entry into epithelial and endothelial cells. J Virol 2008, 82:60-70.
70. Revello M.G., Gerna G. Human cytomegalovirus tropism for endothelial/epithelial cells: scientific background and clinical implications. Rev Med Virol 2010, 20:136-155.
71. Cui X., Lee R., Adler S.P., McVoy M.A. Antibody inhibition of human cytomegalovirus spread in epithelial cell cultures. J Virol Methods 2013, 192:44-50.
72. Lilleri D., Kabanova A., Lanzavecchia A., Gerna G. Antibodies against neutralization epitopes of human cytomegalovirus gH/gL/pUL128-130-131 complex and virus spreading may correlate with virus control in vivo. J Clin Immunol 2012, 32:1324-1331.
73. Compton T. Receptors and immune sensors: the complex entry path of human cytomegalovirus. Trends Cell Biol 2004, 14:5-8.
74. Wang D., Li F., Freed D.C., Finnefrock A.C., Tang A., Grimes S.N., et al. Quantitative analysis of neutralizing antibody response to human cytomegalovirus in natural infection. Vaccine 2011, 29:9075-9080.
75. Macagno A., Bernasconi N.L., Vanzetta F., Dander E., Sarasini A., Revello M.G., et al. Isolation of human monoclonal antibodies that potently neutralize human cytomegalovirus infection by targeting different epitopes on the gH/gL/UL128-131A complex. J Virol 2010, 84:1005-1013.
76. Mocarski E.S., Bonyhadi M., Salimi S., McCune J.M., Kaneshima H. Human cytomegalovirus in a SCID-hu mouse: thymic epithelial cells are prominent targets of viral replication. Proc Natl Acad Sci U S A 1993, 90:104-108.
77. Wang W., Taylor S.L., Leisenfelder S.A., Morton R., Moffat J.F., Smirnov S., et al. Human cytomegalovirus genes in the 15-kilobase region are required for viral replication in implanted human tissues in SCID mice. J Virol 2005, 79:2115-2123.
78. Shultz L.D., Brehm M.A., Garcia-Martinez J.V., Greiner D.L. Humanized mice for immune system investigation: progress, promise and challenges. Nat Rev Immunol 2012, 12:786-798.
79. Cannon M.J., Westbrook K., Levis D., Schleiss M.R., Thackeray R., Pass R.F. Awareness of and behaviors related to child-to-mother transmission of cytomegalovirus. Prevent Med 2012, 54:351-357.
80. Zanghellini F., Boppana S.B., Emery V.C., Griffiths P.D., Pass R.F. Asymptomatic primary cytomegalovirus infection: virologic and immunologic features. J Infect Dis 1999, 180:702-707.
81. Adler B., Sinzger C. Endothelial cells in human cytomegalovirus infection: one host cell out of many or a crucial target for virus spread. Thromb Haemost 2009, 102:1057-1063.
82. Adler S.P., Marshall B. Cytomegalovirus infections. Pediatr Rev/Am Acad Pediatr 2007, 28:92-100.
83. Gerna G. Endothelial cells and CMV dissemination. Future Microbiol 2012, 7:441-444.
84. Smith M.S., Bentz G.L., Alexander J.S., Yurochko A.D. Human cytomegalovirus induces monocyte differentiation and migration as a strategy for dissemination and persistence. J Virol 2004, 78:4444-4453.
85. Smith M.G. Propagation in tissue cultures of a cytopathogenic virus from human salivary gland virus (SGV) disease. Proc Soc Exp Biol Med 1956, 92:424-430.
86. Saccoccio F.M., Gallagher M.K., Adler S.P., McVoy M.A. Neutralizing activity of saliva against cytomegalovirus. Clin Vaccine Immunol 2011, 18:1536-1542.
87. Arora N., Novak Z., Fowler K.B., Boppana S.B., Ross S.A. Cytomegalovirus viruria and DNAemia in healthy seropositive women. J Infect Dis 2010, 202:1800-1803.
88. Meyer H., Sundqvist V.A., Pereira L., Mach M. Glycoprotein gp116 of human cytomegalovirus contains epitopes for strain-common and strain-specific antibodies. J Gen Virol 1992, 73(Pt 9):2375-2383.
89. Pignatelli S., Dal Monte P., Rossini G., Landini M.P. Genetic polymorphisms among human cytomegalovirus (HCMV) wild-type strains. Rev Med Virol 2004, 14:383-410.
90. Novak Z., Ross S.A., Patro R.K., Pati S.K., Kumbla R.A., Brice S., et al. Cytomegalovirus strain diversity in seropositive women. J Clin Microbiol 2008, 46:882-886.
91. Adler S.P., McVoy M. Detection of cytomegalovirus antibody by enzyme immunoassay and lack of evidence for an effect resulting from strain heterogeneity. J Clin Microbiol 1986, 24:870-872.
92. Novak Z., Ross S.A., Patro R.K., Pati S.K., Reddy M.K., Purser M., et al. Enzyme-linked immunosorbent assay method for detection of cytomegalovirus strain-specific antibody responses. Clin Vaccine Immunol 2009, 16:288-290.
93. Revello M.G., Campanini G., Piralla A., Furione M., Percivalle E., Zavattoni M., et al. Molecular epidemiology of primary human cytomegalovirus infection in pregnant women and their families. J Med Virol 2008, 80:1415-1425.
94. Pereira L., Maidji E. Cytomegalovirus infection in the human placenta: maternal immunity and developmentally regulated receptors on trophoblasts converge. Curr Top Microbiol Immunol 2008, 325:383-395.
95. Lilleri D., Kabanova A., Revello M.G., Percivalle E., Sarasini A., Genini E., et al. Fetal human cytomegalovirus transmission correlates with delayed maternal antibodies to gH/gL/pUL128-130-131 complex during primary infection. PloS ONE 2013, 8:e59863.
96. Furione M., Rognoni V., Sarasini A., Zavattoni M., Lilleri D., Gerna G., et al. Slow increase in IgG avidity correlates with prevention of human cytomegalovirus transmission to the fetus. J Med Virol 2013, 85:1960-1967.
97. Maidji E., McDonagh S., Genbacev O., Tabata T., Pereira L. Maternal antibodies enhance or prevent cytomegalovirus infection in the placenta by neonatal Fc receptor-mediated transcytosis. Am J Pathol 2006, 168:1210-1226.
98. Renzette N., Bhattacharjee B., Jensen J.D., Gibson L., Kowalik T.F. Extensive genome-wide variability of human cytomegalovirus in congenitally infected infants. PLoS Pathog 2011, 7:e1001344.
99. Renzette N., Gibson L., Bhattacharjee B., Fisher D., Schleiss M.R., Jensen J.D., et al. Rapid intrahost evolution of human cytomegalovirus is shaped by demography and positive selection. PLoS Genet 2013, 9:e1003735.
100. Adler S.P. Screening for cytomegalovirus during pregnancy. Infect Dis Obstetr Gynecol 2011, 2011:1-9.
101. Buxmann H., Stackelberg O.M., Schlosser R.L., Enders G., Gonser M., Meyer-Wittkopf M., et al. Use of cytomegalovirus hyperimmunoglobulin for prevention of congenital cytomegalovirus disease: a retrospective analysis. J Perinat Med 2012, 40:439-446.
102. Nigro G., Adler S.P., La Torre R., Best A.M. Passive immunization during pregnancy for congenital cytomegalovirus infection. N Engl J Med 2005, 353:1350-1362.
103. Nigro G., Adler S.P., Parruti G., Anceschi M.M., Coclite E., Pezone I., et al. Immunoglobulin therapy of fetal cytomegalovirus infection occurring in the first half of pregnancy-a case-control study of the outcome in children. J Infect Dis 2012, 205:215-227.
104. Visentin S., Manara R., Milanese L., Da Roit A., Forner G., Salviato E., et al. Early primary cytomegalovirus infection in pregnancy: maternal hyperimmunoglobulin therapy improves outcomes among infants at 1 year of age. Clin Infect Dis 2012, 55:497-503.
105. Revello M.G., Lilleri D., Zavattoni M., Furione M., Genini E., Comolli G., et al. Lymphoproliferative response in primary human cytomegalovirus (HCMV) infection is delayed in HCMV transmitter mothers. J Infect Dis 2006, 193:269-276.
106. Lilleri D., Fornara C., Furione M., Zavattoni M., Revello M.G., Gerna G. Development of human cytomegalovirus-specific T cell immunity during primary infection of pregnant women and its correlation with virus transmission to the fetus. J Infect Dis 2007, 195:1062-1070.
107. Fu T.M., Wang D., Freed D.C., Tang A., Li F., He X., et al. Restoration of viral epithelial tropism improves immunogenicity in rabbits and rhesus macaques for a whole virion vaccine of human cytomegalovirus. Vaccine 2012, 30:7469-7474.
108. Freed D.C., Tang Q., Tang A., Li F., He X., Huang Z., et al. Pentameric complex of viral glycoprotein H is the primary target for potent neutralization by a human cytomegalovirus vaccine. Proc Natl Acad Sci U S A 2013.
109. Plotkin S.A., Starr S.E., Friedman H.M., Brayman K., Harris S., Jackson S., et al. Effect of Towne live virus vaccine on cytomegalovirus disease after renal transplant. A controlled trial. Ann Internal Med 1991, 114:525-531.
110. Cayatte C., Schneider-Ohrum K., Wang Z., Irrinki A., Nguyen N., Lu J., et al. Cytomegalovirus vaccine strain Towne-derived dense bodies induce broad cellular immune responses and neutralizing antibodies that prevent infection of fibroblasts and epithelial cells. J Virol 2013, 87:11107-11120.
111. Pepperl S., Munster J., Mach M., Harris J.R., Plachter B. Dense bodies of human cytomegalovirus induce both humoral and cellular immune responses in the absence of viral gene expression. J Virol 2000, 74:6132-6146.
112. Bernstein D.I., Schleiss M.R., Berencsi K., Gonczol E., Dickey M., Khoury P., et al. Effect of previous or simultaneous immunization with canarypox expressing cytomegalovirus (CMV) glycoprotein B (gB) on response to subunit gB vaccine plus MF59 in healthy CMV-seronegative adults. J Infect Dis 2002, 185:686-690.
113. Kharfan-Dabaja M.A., Boeckh M., Wilck M.B., Langston A.A., Chu A.H., Wloch M.K., et al. A novel therapeutic cytomegalovirus DNA vaccine in allogeneic haemopoietic stem-cell transplantation: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Infect Dis 2012, 12:290-299.
114. Jacobson M.A., Adler S.P., Sinclair E., Black D., Smith A., Chu A., et al. A CMV DNA vaccine primes for memory immune responses to live-attenuated CMV (Towne strain). Vaccine 2009, 27:1540-1548.
115. Shedlock D.J., Talbott K.T., Wu S.J., Wilson C.M., Muthumani K., Boyer J.D., et al. Vaccination with synthetic constructs expressing cytomegalovirus immunogens is highly T cell immunogenic in mice. Hum Vaccines Immunother 2012, 8:1668-1681.
116. Reap E.A., Morris J., Dryga S.A., Maughan M., Talarico T., Esch R.E., et al. Development and preclinical evaluation of an alphavirus replicon particle vaccine for cytomegalovirus. Vaccine 2007, 25:7441-7449.
117. Bernstein D.I., Reap E.A., Katen K., Watson A., Smith K., Norberg P., et al. Randomized, double-blind, Phase 1 trial of an alphavirus replicon vaccine for cytomegalovirus in CMV seronegative adult volunteers. Vaccine 2009, 28:484-493.
118. Loomis R.J., Lilja A.E., Monroe J., Balabanis K.A., Brito L.A., Palladino G., et al. Vectored co-delivery of human cytomegalovirus gH and gL proteins elicits potent complement-independent neutralizing antibodies. Vaccine 2013, 31:919-926.
119. Adler S.P., Plotkin S.A., Gonczol E., Cadoz M., Meric C., Wang J.B., et al. A canarypox vector expressing cytomegalovirus (CMV) glycoprotein B primes for antibody responses to a live attenuated CMV vaccine (Towne). J Infect Dis 1999, 180:843-846.
120. Berencsi K., Gyulai Z., Gonczol E., Pincus S., Cox W.I., Michelson S., et al. A canarypox vector-expressing cytomegalovirus (CMV) phosphoprotein 65 induces long-lasting cytotoxic T cell responses in human CMV-seronegative subjects. J Infect Dis 2001, 183:1171-1179.
121. Wang Z., La Rosa C., Lacey S.F., Maas R., Mekhoubad S., Britt W.J., et al. Attenuated poxvirus expressing three immunodominant CMV antigens as a vaccine strategy for CMV infection. J Clin Virol 2006, 35:324-331.
122. Wang Z., La Rosa C., Maas R., Ly H., Brewer J., Mekhoubad S., et al. Recombinant modified vaccinia virus Ankara expressing a soluble form of glycoprotein B causes durable immunity and neutralizing antibodies against multiple strains of human cytomegalovirus. J Virol 2004, 78:3965-3976.
123. Rist M., Cooper L., Elkington R., Walker S., Fazou C., Tellam J., et al. Ex vivo expansion of human cytomegalovirus-specific cytotoxic T cells by recombinant polyepitope: implications for HCMV immunotherapy. Eur J Immunol 2005, 35:996-1007.
124. La Rosa C., Longmate J., Lacey S.F., Kaltcheva T., Sharan R., Marsano D., et al. Clinical evaluation of safety and immunogenicity of PADRE-cytomegalovirus (CMV) and tetanus-CMV fusion peptide vaccines with or without PF03512676 adjuvant. J Infect Dis 2012, 205:1294-1304.
125. Saccoccio F.M., Sauer A.L., Cui X., Armstrong A.E., Habib el S.E., Johnson D.C., et al. Peptides from cytomegalovirus UL130 and UL131 proteins induce high titer antibodies that block viral entry into mucosal epithelial cells. Vaccine 2011, 29:2705-2711.